Last reviewed · How we verify
Endocrine Therapy 2 (endocrine-therapy-2)
Endocrine Therapy 2
Endocrine Therapy 2 is a hormone-based cancer treatment that works by blocking or replacing hormones that fuel certain hormone-sensitive cancers. It is primarily approved for hormone receptor-positive breast cancer and offers a targeted approach to prevent cancer growth by disrupting the hormonal signals cancer cells depend on.
At a glance
| Generic name | endocrine-therapy-2 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Endocrine Therapy 2 |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Endocrine Therapy 2 works by interfering with the hormonal pathways that certain cancers rely on to survive and proliferate. Many cancers, particularly some breast cancers, contain receptors on their surface that respond to hormones like estrogen. When these hormones attach to the receptors, they send a growth signal to the cancer cell. Endocrine Therapy 2 blocks this process by either preventing the hormone from reaching the receptor or reducing the amount of hormone available in the body. By cutting off these growth signals, the drug effectively starves cancer cells of the chemical messages they need to multiply. This allows the immune system and the body's natural defenses to better control or eliminate the cancer cells. The therapy is particularly effective because it targets the specific vulnerability of hormone-sensitive cancers without affecting cells that don't rely on these hormonal signals. This approach has become a cornerstone of cancer treatment for certain types of tumors, offering patients a more targeted therapy option that often has fewer side effects than chemotherapy while still providing meaningful disease control and improved survival outcomes.
Approved indications
Pipeline indications
- HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer — discontinued
Common side effects
Key clinical trials
- Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurre (discontinued)
- To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutane (discontinued)
- Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) (discontinued)
- Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (discontinued)
- A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction (discontinued)
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have (discontinued)
- Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiolo (discontinued)
- A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiratero (discontinued)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endocrine Therapy 2 CI brief — competitive landscape report
- Endocrine Therapy 2 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI